Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit

  • 0 views
  • 15 Sep, 2021
  • 3 locations
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

, ceritinib and brigatinib are second-generation ITK-ALK. They have been shown to be effective in the first line of treatment in randomized trials. Alectinib has shown superiority to crizotinib as the first

  • 0 views
  • 26 Jan, 2021
  • 30 locations
Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC

ceritinib as the first ALK tyrosine kinase inhibitor (TKI)therapy.

cancer treatment
lymphoma
anaplastic lymphoma
cancer
lorlatinib
  • 0 views
  • 27 Aug, 2021
  • 39 locations
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA) given in combination with trametinib (MEKINIST) in patients who have progressed on prior melanoma

trametinib
solid tumors
BRAF
unresectable melanoma
cytotoxic t-lymphocyte antigen 4
  • 1 views
  • 12 Aug, 2021
  • 1 location
Ceritinib Plus Docetaxel in ALK-Negative EGFR WT Advanced NSCLC

The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia) used in combination with docetaxel (Taxotere) will have on participants and their cancer. The

lung cancer
taxotere
cancer
metastasis
EGFR
  • 8 views
  • 24 Jun, 2021
  • 2 locations
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

This is a phase I/II study of ceritinib and trametinib in Stage IIIB or IV anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). The Phase I portion will investigate

potassium
neutrophil count
tyrosine
alopecia
cancer chemotherapy
  • 24 views
  • 26 Jul, 2021
  • 3 locations
Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

This phase I trial studies the side effects and best dose of ceritinib and everolimus in treating patients with solid tumors that have spread from where they started to nearby tissue or lymph

aptt
liver metastasis
systemic therapy
lung cancer
neutrophil count
  • 37 views
  • 24 Jan, 2021
  • 1 location
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs …

progressive disease
neutrophil count
serum bilirubin level
alopecia
metastasis
  • 0 views
  • 24 Jan, 2021
  • 4 locations
Study of Lorlatinib in ROS1 Rearranged NSCLC

This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.

cancer chemotherapy
proto-oncogene tyrosine-protein kinase ros
recurrent non-small cell lung cancer
measurable disease
ROS1
  • 0 views
  • 25 Jan, 2021
  • 1 location
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Lung cancer remains the most lethal malignancy in both sexes around the world. It is estimated that lung cancer caused 234,030 deaths in the United States in 2016, accounting for 28% of all cancer-related deaths. In 2012 alone, a total of 6,697 deaths from lung cancer were registered in Mexico; …

  • 0 views
  • 18 Feb, 2021
  • 1 location